VJOncology is committed to improving our service to you

ESMO 2017 | Is there a use for palbociclib in the treatment of pancreatic neuroendocrine tumors?

VJOncology is committed to improving our service to you

Enrique Grande

Enrique Grande, MD, from the Ramon y Cajal University Hospital, Madrid, Spain, discusses the use of palbocilib at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The PALBONET study (NCT02806648), a Phase II, non-randomized, single arm trial investigated the activity and safety of palbociclib, a CDK4/6 inhibitor in pancreatic neuroendocrine tumors. Unfortunately, this study found that no patients responded to palbociclib. There is potential for this drug to be used in combination in the future, due to its safety profile, however, Dr Grande states that this is not currently being pursued.

Share this video  
8th September 2017

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter